| |
Don’t fall behind. Download our eBook to understand the pillars that define connected healthcare information. Gain insight into how your team can create a solid, reliable data foundation built on privacy and trust to drive patient innovation forward! 
|
|
|
Global obesity rates continue to rise and the search for safer and more effective treatments is accelerating. Download the QPS Obesity White Paper to learn more about obesity drug development and how QPS, a global full-service CRO, is leading the way. +(1).png)
|
|
| By Kevin Dunleavy A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.” In declaring the end of the shortage, the FDA has halted the ability of compounding pharmacies to manufacture the in-demand products. |
|
|
|
By Nick Paul Taylor The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an interim look at the data showed the TAR-200 candidate was no better than chemoradiation. |
By Zoey Becker Activist investor Starboard Value recently picked up a $1 billion stake in the drugmaker and will now pitch a strategy shift to top executives, the Financial Times reported. |
By Fraiser Kansteiner Following the recent closure of its manufacturing facility in Marion, North Carolina, from flooding caused by Hurricane Helene, Baxter is providing some clarity on remediation timelines. |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
By Gabrielle Masson As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with quarterly layoffs evening out to similar levels as the same time last year. |
By Kevin Dunleavy Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey and one that may serve as instructive for future drug discovery. |
By Conor Hale Cologuard Plus represents the next generation of the company's mainstay, at-home screening test for colorectal cancer. |
By Darren Incorvaia The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists the 2024 Nobel Prize in Physiology or Medicine for their discovery of microRNA, the small RNA molecules that regulate genes, one year after the prize went to scientists who conducted foundational work on mRNA vaccines. |
By Darren Incorvaia A day after the Physics prize was given to two scientists for foundational work on machine learning, the Nobel Prize in Chemistry has been awarded to three scientists who used advanced computational methods to solve a decades-old problem. |
By Angus Liu BeiGene is pricing Tevimbra at a 10% discount to other PD-1 therapies available in second-line esophageal squamous cell carcinoma. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Fierce Healthcare's Emma Beavins chats with Healthy.io CEO Geoff Martin about how his company is helping to address the hidden crisis of chronic kidney disease. |
|
|---|
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Cognizant, in partnership with Microsoft, have interviewed 200 medtech decision makers across the UK, Ireland, France, Germany and the USA to find out about what the future holds. A responsible AI framework is going to be key. Read our report to learn more. Sponsored by: Cognizant and Microsoft |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Navigating the Path to Medication Adherence: Overcoming 8 Key Challenges Sponsored by: Quest Diagnostics |
Whitepaper Open up unexpected opportunities. This digital story offers pharma marketers proactive strategies for helping patients discover and switch to treatments, even if they aren’t actively looking to make a change. Sponsored by: Healthline Media |
Whitepaper Blood-based biomarker testing presents a promising solution to improve access to critical early risk assessment along with a pathway towards accelerated clinical trials for Alzheimer's Disease. Sponsored by: Quest Diagnostics |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
